David Harries, MD
Interventional Pain Medicine · Watford City, NDNPI 1104924109
Payments from drug & device makers
Across 61 payments — averaging $52.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertos Medical, Inc.$1K
- Medtronic$463
- Nevro Corp.$369
- Abbott$166
- AstraZeneca$142
- AbbVie$136
- plus $427 from 11 others
What the payments were for
- Consulting fees$1,00031%
- Travel & lodging$48015%
- Food & beverage$1,70253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertos Medical, Inc. | 4 | $1,480 |
| Medtronic(2 entities) | 20 | $463 |
| Nevro Corp. | 8 | $369 |
| Abbott | 4 | $166 |
| AstraZeneca | 2 | $142 |
| AbbVie(2 entities) | 8 | $136 |
| Stimwave Technologies Incorporated | 1 | $99 |
| Amgen | 3 | $64 |
| Relievant Medsystems, Inc. | 1 | $61 |
| Lilly USA, LLC | 2 | $58 |
| Stryker | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Avanos Medical | 1 | $12 |
| Boston Scientific | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- mild Device Kit$1,480
- Senza Spinal Cord Stimulation System$294
- RESTORE$126
- Strensiq$125
- INTELLIS ADAPTIVESTIM$121
How this compares
Too few interventional pain medicine providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 14 | $3,385 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 24 | $588 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $447 |
| Tramadol Hcl | 25 | $320 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $184 |
| Pregabalin | 11 | $142 |
| Gabapentin | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Watford City
- Majid GhaziFargo$7K
- Hamzah RamawadFargo$5K
- Sara VandrovecFargo$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.